Verrica Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Verrica Pharmaceuticals Inc. (VRCA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 15.82 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 7.90K shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 7.92K shares, a 99.40% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 42.27K shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-06-30 was -1.14M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month |
|---|---|---|---|
| 2026-06-30 | 7.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 15.82K shares 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 7.92K shares 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | 42.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -1.09M shares derived: sum of 2 quarters · filed 2025-11-14 | 220.36K shares 10-Q · filed 2025-11-14 |
| 2025-06-30 | -1.14M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 178.09K shares 10-Q · filed 2025-08-12 | |
| 2025-03-31 | 1.31M shares 10-Q · filed 2025-05-13 | ||
| 2024-09-30 | 104.60K shares 10-Q · filed 2024-11-05 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-13 | ||
| 2023-03-31 | 8.00K shares 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | 142.37K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 151.83K shares derived: sum of 2 quarters · filed 2022-11-07 | 177.45K shares 10-Q · filed 2022-11-07 |
| 2022-06-30 | 9.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 35.09K shares 10-Q · filed 2022-08-11 | |
| 2022-03-31 | 25.62K shares 10-Q · filed 2022-05-09 | ||
| 2021-09-30 | 2.34K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 16.55K shares 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 14.21K shares 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |